Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.69 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | GNRHR | P30968 | 1/20 | 0.45 |
| ▸ | IL1B | P01584 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5777100 | 0.90 | KCNH2 (0.55) | HTR3AHTR4KCNH2KDM4EPKM | |
| SCHEMBL5889579 | 0.85 | KCNH2 (0.77) | HTR3AHTR4KCNH2 | |
| SCHEMBL6703420 | 0.84 | HTR4 (0.71) | HTR3AHTR4KCNH2 | |
| SCHEMBL6246478 | 0.84 | KCNH2 (0.76) | HTR3AHTR4KCNH2 | |
| SCHEMBL5889452 | 0.84 | KCNH2 (0.73) | HTR3AHTR4KCNH2 | |
| SCHEMBL6275571 | 0.83 | KCNH2 (0.75) | HTR3AHTR4KCNH2 | |
| SCHEMBL5889421 | 0.82 | KCNH2 (0.71) | HTR3AHTR4KCNH2 | |
| SCHEMBL5889426 | 0.82 | KCNH2 (0.71) | HTR3AHTR4KCNH2 | |
| SCHEMBL6702946 | 0.82 | KCNH2 (0.73) | HTR3AHTR4KCNH2 | |
| SCHEMBL6314948 | 0.82 | KCNH2 (0.81) | HTR3AHTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR3A 35/4885HTR4 1/4885KCNH2 1390/4885 |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | HTR4, HRH4, GIPR | HTR3A 11/4885HTR4 1/4885KCNH2 1253/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | HTR3A 35/4885HTR4 1/4885KCNH2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.